Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 6, 2003

View Archived Issues

MorphoSys and Schering AG collaboration yields positive animal data

MedImmune and Critical Therapeutics to develop drugs targeting HMGB-1

Fulvestrant at least as effective as anastrozole in advanced breast cancer

Ariad summarizes recent important findings

FDA requests additional information in support of Hemopure BLA

GPC Biotech makes progress on various fronts with 1D09C3

Happy Valley Medical licenses Ceracor to Edwards Lifesciences

NeoGenesis and Amgen form R&D collaboration

Squalamine improves visual outcomes in phase I/II wet AMD study

CV Therapeutics and FDA agree to cancel Ranexa review

Chiron licenses HCV technology to Gilead for drug development efforts

Novel HCV NS3 protease inhibitors under study at BMS

Antibacterial quaternary ammonium salts, their preparation and use reported by Toagosei

JT patent covers new inhibitors of sodium-phosphate cotransporter and their use

Two novel series of lanosterol synthase inhibitors in early development at Roche

New antitumor agents in Kyowa Hakko development pipeline

ARS scientists design GILZ-based peptides for use in cancer, inflammation, etc.

Irreversible inhibition of CYP3A4 described for tabimorelin in humans

Astralis cleared to begin phase I testing of Psoraxine in U.S.

Submission of European MAA, U.S. sNDA for Angiomax

FDA approves Photofrin PDT for high-grade dysplasia in Barrett's esophagus

Novel antibiotics targeting pantothenate kinase

Kirin Brewery licenses antibody technology to Takeda

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026